Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.
Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.
Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Kura Oncology (KURA) saw its shares rise almost 7% in the last trading session.
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.
Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI
by Zacks Equity Research
Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI
Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)
by Zacks Equity Research
Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
5 Profitability Stocks to Make the Most of Trump Bump
by Zacks Equity Research
Net income ratio selects the best profitable company on the back of Trump-led rally.
3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock
by Zacks Equity Research
Cytokinetics (CYTK) may prove to be a fresh pick that has potential to move in the right direction and is seeing momentum.
Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
by Zacks Equity Research
Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
Cytokinetics (CYTK): An Off-the-Radar Potential Winner
by Zacks Equity Research
Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for Cytokinetics (CYTK) and that now might be an interesting buying opportunity.
5 Profitable Stocks to Buy for Great Returns
by Zacks Equity Research
Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.
New Strong Buy Stocks for December 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
3 Biotech Stocks to Turn the Tide This Earnings Season
by Zacks Equity Research
The biotech sector has strong fundamentals, and healthy product pipelines.
4 Biotech Stocks Looking Good this Earnings Season
by Zacks Equity Research
the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.
5 Stocks Rocketing to New Highs
by David Bartosiak
These 5 stocks are breaking out to new highs on good volume